Phitsamai A, Chueansuwan W, Changpradub D
Cureus. 2022; 14(4):e24393.
PMID: 35619836
PMC: 9126442.
DOI: 10.7759/cureus.24393.
Bisharat N, Koton Y, Oliver J
Microbiologyopen. 2020; 9(9):e1103.
PMID: 32779403
PMC: 7520988.
DOI: 10.1002/mbo3.1103.
Ho Y, Hung F, Weng C, Li W, Chuang T, Liu T
J Biomed Sci. 2017; 24(1):54.
PMID: 28800764
PMC: 5554404.
DOI: 10.1186/s12929-017-0361-9.
Koton Y, Gordon M, Chalifa-Caspi V, Bisharat N
Front Microbiol. 2015; 5:803.
PMID: 25642229
PMC: 4295529.
DOI: 10.3389/fmicb.2014.00803.
Yokochi N, Tanaka S, Matsumoto K, Oishi H, Tashiro Y, Yoshikane Y
PLoS One. 2013; 8(1):e55219.
PMID: 23383115
PMC: 3559389.
DOI: 10.1371/journal.pone.0055219.
Does Vibrio vulnificus present a health threat to Canadians?.
Stavric S, Buchanan B
Can J Infect Dis. 2012; 8(5):279-85.
PMID: 22346524
PMC: 3250891.
DOI: 10.1155/1997/756754.
Integrative genome-scale metabolic analysis of Vibrio vulnificus for drug targeting and discovery.
Kim H, Kim S, Jeong H, Kim T, Kim J, Choy H
Mol Syst Biol. 2011; 7:460.
PMID: 21245845
PMC: 3049409.
DOI: 10.1038/msb.2010.115.
Predictors of mortality in skin and soft-tissue infections caused by Vibrio vulnificus.
Kuo Chou T, Chao W, Yang C, Wong R, Ueng K, Chen S
World J Surg. 2010; 34(7):1669-75.
PMID: 20151130
DOI: 10.1007/s00268-010-0455-y.
Primary Shewanella algae bacteremia mimicking Vibrio septicemia.
Myung D, Jung Y, Kang S, Song Y, Park K, Jung S
J Korean Med Sci. 2009; 24(6):1192-4.
PMID: 19949681
PMC: 2775873.
DOI: 10.3346/jkms.2009.24.6.1192.
The pyrH gene of Vibrio vulnificus is an essential in vivo survival factor.
Lee S, Kim S, Kim C, Kim M, Kim Y, Jeong K
Infect Immun. 2007; 75(6):2795-801.
PMID: 17371864
PMC: 1932866.
DOI: 10.1128/IAI.01499-06.
Atypical manifestation of Vibrio vulnificus septicaemia.
Lin L, Hung S, Lin C, Liu C, Chong C
Emerg Med J. 2006; 23(6):e39.
PMID: 16714493
PMC: 2564381.
DOI: 10.1136/emj.2005.032573.
Specificity of a Vibrio vulnificus aminopeptidase toward kinins and other peptidyl substrates.
Richards G, Nunez A
J Bacteriol. 2006; 188(6):2056-62.
PMID: 16513735
PMC: 1428149.
DOI: 10.1128/JB.188.6.2056-2062.2006.
A calcium-calmodulin antagonist blocks experimental Vibrio vulnificus cytolysin-induced lethality in an experimental mouse model.
Lee Y, Park K, Lin Z, Kho Y, Park J, Rho H
Infect Immun. 2004; 72(10):6157-9.
PMID: 15385523
PMC: 517569.
DOI: 10.1128/IAI.72.10.6157-6159.2004.
Comparative genome analysis of Vibrio vulnificus, a marine pathogen.
Chen C, Wu K, Chang Y, Chang C, Tsai H, Liao T
Genome Res. 2003; 13(12):2577-87.
PMID: 14656965
PMC: 403799.
DOI: 10.1101/gr.1295503.
In vitro and in vivo activities of newer fluoroquinolones against Vibrio vulnificus.
Tang H, Chang M, Ko W, Huang K, Lee C, Chuang Y
Antimicrob Agents Chemother. 2002; 46(11):3580-4.
PMID: 12384368
PMC: 128723.
DOI: 10.1128/AAC.46.11.3580-3584.2002.
Cloning and characterization of a periplasmic nuclease of Vibrio vulnificus and its role in preventing uptake of foreign DNA.
WU S, Lo S, Shao C, Tsai H, Hor L
Appl Environ Microbiol. 2001; 67(1):82-8.
PMID: 11133431
PMC: 92521.
DOI: 10.1128/AEM.67.1.82-88.2001.
Vibrio vulnificus has the transmembrane transcription activator ToxRS stimulating the expression of the hemolysin gene vvhA.
Lee S, Shin S, Kim S, Kim Y, Shin D, Chung S
J Bacteriol. 2000; 182(12):3405-15.
PMID: 10852871
PMC: 101907.
DOI: 10.1128/JB.182.12.3405-3415.2000.
Direct identification of Vibrio vulnificus in clinical specimens by nested PCR.
Lee S, Kim S, Kim S, Kim H, Shin J, Choi S
J Clin Microbiol. 1998; 36(10):2887-92.
PMID: 9738039
PMC: 105083.
DOI: 10.1128/JCM.36.10.2887-2892.1998.
Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection.
Chuang Y, Ko W, Wang S, Liu J, Kuo C, Wu J
Antimicrob Agents Chemother. 1998; 42(6):1319-22.
PMID: 9624467
PMC: 105595.
DOI: 10.1128/AAC.42.6.1319.
Thermal-death times of opaque and translucent morphotypes of Vibrio vulnificus.
Kim C, Jeong K, Rhee J, Choi S
Appl Environ Microbiol. 1997; 63(8):3308-10.
PMID: 9251221
PMC: 168632.
DOI: 10.1128/aem.63.8.3308-3310.1997.